MICHELLE MARTIN: Open Payments
NPI 1053731406 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,941 in 161 payments from 29 companies in 2025. Trend: 2023 $2,016 · 2024 $3,747 · 2025 $3,941
Food & beverage: $3,941
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 14 | $471 |
| ABBVIE INC. | 21 | $413 |
| Eisai Inc. | 11 | $339 |
| PFIZER INC. | 14 | $317 |
| Biogen, Inc. | 13 | $256 |
| EMD Serono, Inc. | 8 | $224 |
| Alexion Pharmaceuticals, Inc. | 8 | $217 |
| SK Life Science, Inc. | 10 | $207 |
| Genentech USA, Inc. | 9 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $174 |
Products named: Leqembi, NURTEC ODT, QULIPTA, ULTOMIRIS, Ocrevus Zunovo, HYQVIA, TYSABRI, Nayzilam.
Industry payments across TX — which companies pay providers there.
